Early initiation of chemotherapy after primary surgery as an adverse prognostic factor in patients with ovarian cancer

Objective: For patients with ovarian cancer (OC), the optimal time to initiate chemotherapy (TTC) after primary surgery is unknown. The aim of this study was to determine the effect of shorter TTC than 14 days on survival after primary surgery for OC among Polish women in 2011. Materials and Methods: All Polish women who underwent a surgical procedure for OC in the period from January 1, 2011 to December 31, 2011 recorded in the Polish National Health Fund Database (PNHFD) were included. The Cox proportional hazard regression analysis was used to compute the adjusted hazard ratio (HR). Results: The 25%, 50%, and 75% quantiles of intervals from surgery to TTC were 21, 30, and 43 days, respectively. In the multivariate analysis, it was observed that the adverse independent prognostic factors were: TTC ≤ 14 days [HR: 1.58 (95%CI: 1.24-2,01); p = 0.0002)] and a surgical procedure other than complex and very extensive excision of the upper part of the sex organs [HR: 2.02 (95%CI: 1.70-2.39); p < 0.0001]. The overall three-year survival rate for longer and shorter TTC than 14 days were 67.8% and 50.3%, respectively (p < 0.0001). Conclusions: This nationwide population-based cohort study revealed a significantly increased risk of death in patients with TTC ≤ 14 days after primary surgery compared with a TTC > 14 days. In order to explain the causes of this phenomenon, it is necessary to conduct a prospective study that randomizes patients to different time intervals. Conclusions: The early initiation of chemotherapy after a primary surgery within 14 days is not a favourable prognostic factor. The nationwide population-based cohort study showed that complex and very extensive excision of the upper part of the sex organs due to ovarian cancer significantly decreased risk of death. In patients with ovarian cancer with comorbidities, the use of chemotherapy shortly, within 14 days, after surgery had unfavourable impact on survival.

Ovarian cancer; Chemotherapy; Primary surgery; Prognostic factors

[1] Openshaw M.R., Fotopoulou C., Blagden S., Gabra H.: “The next steps in improving the outcomes of advanced ovarian cancer”. Womens Health Lond. Engl., 2015, 11, 355.

[2] Lowe K.A., Chia V.M., Taylor A., O’Malley C., Kelsh M., Mohamed M., et al.: “An international assessment of ovarian cancer incidence and mortality”. Gynecol. Oncol., 2013, 130, 107.

[3] GLOBOCAN 2012. Available at: http://globocan.iarc.fr/old/sum- mary_table_pop-html.asp?selection=156616&title=Poland&sex= 2&type=1&window=1&sort=1&submit=%C2%A0Execute%C2%A0

[4] Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., et al.: “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012”. Int. J. Cancer, 2015, 136, E359.

[5] Bristow R.E., Chang J., Ziogas A., Anton-Culver H.: “Adherence to treatment guidelines for ovarian cancer as a measure of quality care”. Obstet. Gynecol., 2013, 121, 1226.

[6] Erickson B.K., Martin J.Y., Shah M.M., Straughn J.M., Leath C.A.: “Reasons for failure to deliver National Comprehensive Cancer Network (NCCN)-adherent care in the treatment of epithelial ovarian cancer at an NCCN cancer center”. Gynecol. Oncol., 2014, 133, 142.

[7] Senkus E., Kyriakides S., Ohno S., Penault-Llorca F., Poortmans P., Rutgers E., et al.: “Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”. Ann. Oncol., 2015, 26, v8.

[8] Schricker T., Lattermann R.: “Perioperative catabolism”. Can. J. Anaesth. J. Can. Anesth., 2015, 62, 182.

[9] Rekomendacje P.T.G.: “dotyczące postępowania w guzach niezłośliwych i raku jajnika”. Edukacja Medyczna.pl n.d. Available at: http://www.edukacjamedyczna.pl/artykul/rekomendacje-ptg- dotyczace-postepowania-w-guzach-niezlosliwych-i-raku- jajnika/4219/0.html

[10] Kong B., Michalski C.W., Friess H., Kleeff J.: “Surgical procedure as an inducer of tumor angiogenesis”. Exp. Oncol., 2010, 32, 186.

[11] Eggermont A.M., Steller E.P., Sugarbaker P.H.: “Laparotomy enhances intraperitoneal tumor growth and abrogates the antitumor effects of interleukin-2 and lymphokine-activated killer cells”. Surgery, 1987, 102, 71.

[12] Goldfarb Y., Sorski L., Benish M., Levi B., Melamed R., Ben-Eliyahu S.: “Improving postoperative immune status and resistance to cancer metastasis: a combined perioperative approach of immunostimulation and prevention of excessive surgical stress responses”. Ann. Surg., 2011, 253, 798.

[13] Goldie J.H., Coldman A.J.: “A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate”. Cancer Treat. Rep., 1979, 63, 1727.

[14] Biagi J.J., Raphael M.J., Mackillop W.J., Kong W., King W.D., Booth C.M.: “Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis”. JAMA, 2011, 305, 2335.

[15] Flynn P.M., Paul J., Cruickshank D.J., Scottish Gynaecological Cancer Trials Group: “Does the interval from primary surgery to chemotherapy influence progression-free survival in ovarian cancer?” Gynecol. Oncol., 2002, 86, 354.

[16] Gadducci A.: “Relationship Between Time Interval From Primary Surgery to the Start of Taxane- Plus Platinum-Based Chemotherapy and Clinical Outcome of Patients With Advanced Epithelial Ovarian Cancer: Results of a Multicenter Retrospective Italian Study”. J. Clin. Oncol., 2005, 23, 751.

[17] Aletti G.D., Long H.J., Podratz K.C., Cliby W.A.: “Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer?” Gynecol. Oncol., 2007, 104, 212.

[18] Lydiksen L., Jensen-Fangel S., Blaakaer J.: “Is it possible to define an optimal time for chemotherapy after surgery for ovarian cancer?” Gynecol. Oncol., 2014, 133, 454.

[19] Omura G., Blessing J.A., Ehrlich C.E., Miller A., Yordan E., Creasman W.T., et al.: “A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study”. Cancer, 1986, 57, 1725.

[20] Wright J.D., Doan T., McBride R., Jacobson J.S., Hershman D.L.: “Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival”. Br. J. Cancer, 2008, 98, 1197.

[21] Puthucheary Z.A., Rawal J., McPhail M., Connolly B., Ratnayake G., Chan P., et al.: “Acute skeletal muscle wasting in critical illness”. JAMA, 2013, 310, 1591.